Ampio Pharmaceuticals, Inc.
AMPE
$0.01
-$0.14-96.39%
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.26% | -42.35% | -18.77% | 15.05% | 32.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.30% | -62.82% | -42.78% | -25.16% | -0.92% |
| Operating Income | 53.30% | 62.82% | 42.78% | 25.16% | 0.92% |
| Income Before Tax | 47.16% | 56.75% | 20.38% | 22.92% | 4.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.16% | 56.75% | 20.38% | 22.92% | 4.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.16% | 56.75% | 20.38% | 22.92% | 4.32% |
| EBIT | 53.30% | 62.82% | 42.78% | 25.16% | 0.92% |
| EBITDA | 51.43% | 62.40% | 43.03% | 25.68% | 0.74% |
| EPS Basic | 48.81% | 58.46% | 25.11% | 29.07% | 15.32% |
| Normalized Basic EPS | 40.32% | 53.02% | 34.25% | 37.30% | 25.36% |
| EPS Diluted | 62.13% | 68.44% | 39.27% | 22.70% | -0.23% |
| Normalized Diluted EPS | 40.31% | 53.02% | 34.16% | 36.91% | 24.40% |
| Average Basic Shares Outstanding | 4.22% | 4.16% | 5.51% | 9.28% | 13.44% |
| Average Diluted Shares Outstanding | 4.22% | 4.16% | 5.36% | 8.43% | 11.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |